LIU Yafei 1,2 , ZHU Hongfei 3,4,5 , LI Ying 1,2 , LAI Honghao 1,2 , ZHOU Qi 6 , LUO Xufei 6 , CHEN Yaolong 6,7,8,9,10 , DENG Hongyong 11 , DU Liang 12 , JIN Yinghui 13 , KONG Dezhao 14 , LI Guowei 15 , LI Jiang 16 , LI Ling 12 , LIAO Xing 17 , LIU Jie 18 , SHI Nannan 17,19 , SHANG Hongcai 20 , TIAN Jinhui 6,7,8,9,10 , WANG Xiaohui 1 , WU Darong 21 , YANG Fengwen 22 , YANG Kehu 6,7,8,9,10 , YU Changhe 20 , ZHANG Jiaxing 23 , ZHAO Chen 17 , GE Long 1,2,7,8,9,10
  • 1. Department of Social Science and Health Management, School of Public Health, Lanzhou University, Lanzhou 730000, P. R. China;
  • 2. Evidence-Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou 730000, P. R. China;
  • 3. School of Public Health, Fudan University, Shanghai 200032, P. R. China;
  • 4. Key Laboratory of Public Health Safety, Fudan University, Shanghai 200032, P. R. China;
  • 5. National Health Commission Key Laboratory of Health Technology Assessment, Fudan University, Shanghai 200032, P. R. China;
  • 6. Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, P. R. China;
  • 7. Institute of Health Data Science, Lanzhou University, Lanzhou 730000, P. R. China;
  • 8. Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, Lanzhou 730000, P. R. China;
  • 9. WHO Collaborating Center for Guideline Implementation and Knowledge Translation, Lanzhou 730000, P. R. China;
  • 10. Chinese GRADE Center, Lanzhou 73000, P. R. China;
  • 11. TCM Health Collaborative Innovation Center, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, P. R. China;
  • 12. Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;
  • 13. Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, P. R. China;
  • 14. Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang 110032, P. R. China;
  • 15. Guangdong Second Provincial General Hospital Affiliated to Jinan University, Guangzhou 510317, P. R. China;
  • 16. Cancer Hospital Chinese Academy of Medical Sciences, Beijing 100021, P. R. China;
  • 17. Institute of Basic Research in Clinical, China Academy of Chinese Medical Sciences, Beijing 100700, P. R. China;
  • 18. Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100700, P. R. China;
  • 19. China Center for Evidence-Based Traditional Chinese Medicine, Beijing 100700, P. R. China;
  • 20. Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine, Beijing 100700, P. R. China;
  • 21. The Second Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine (Guangdong Hospital of Traditional Chinese Medicine), Guangzhou 510120, P. R. China;
  • 22. Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P. R. China;
  • 23. Department of Pharmacy, Guizhou Provincial People’s Hospital, Guiyang 550002, P. R. China;
GE Long, Email: gelong2009@163.com
Export PDF Favorites Scan Get Citation

In the clinical evidence-based decision-making process, factors including benefits and harms, evidence certainty, cost and feasibility of interventions should be considered based on the best evidence. The development of decision threshold of effect size (DTES) for patient health outcomes can help stakeholders understand the benefits and harms of interventions, assess evidence certainty, and interpret research results. Based on international experience, the MERGE Working Group through group discussions, semi-structured interviews, expert consensus, and pilot application developed a set of 8-step guidelines for the development of DTES for health outcomes. These steps included necessity assessment, formation of working groups, selection of patient important outcomes, creation of scenarios based on the best evidence, design of expert consultation questionnaires, analysis of expert consultation results, face-to-face expert consensus, dissemination of the application and reevaluation. The DTES guideline development is intended to provide methodological guidance for stakeholders to develop DTES for health outcome indicators in different domains.

Citation: LIU Yafei, ZHU Hongfei, LI Ying, LAI Honghao, ZHOU Qi, LUO Xufei, CHEN Yaolong, DENG Hongyong, DU Liang, JIN Yinghui, KONG Dezhao, LI Guowei, LI Jiang, LI Ling, LIAO Xing, LIU Jie, SHI Nannan, SHANG Hongcai, TIAN Jinhui, WANG Xiaohui, WU Darong, YANG Fengwen, YANG Kehu, YU Changhe, ZHANG Jiaxing, ZHAO Chen, GE Long. A guideline for determining the effect size decision threshold of health outcomes. Chinese Journal of Evidence-Based Medicine, 2024, 24(4): 405-413. doi: 10.7507/1672-2531.202308133 Copy

  • Previous Article

    Guidelines for high-flow nasal cannula oxygen therapy in neonates (2023)
  • Next Article

    Study on regional and urban-rural disparities in the hypertension incidence of Chinese adults: based on longitudinal dynamic cohort of CHNS